Theratechnologies(US:THTX) Globenewswire·2025-04-09 11:30Core Insights - Theratechnologies reported a total revenue of $19 million for Q1 2025, reflecting a year-over-year growth of 17% [2][14] - The company achieved a net profit of $117,000, a significant improvement from a net loss of $4.48 million in Q1 2024 [28] - The approval of EGRIFTA WR™ by the FDA is expected to enhance the company's growth trajectory in the HIV treatment market [3][35] Financial Performance - EGRIFTA SV net sales reached $13.88 million, up 44.8% from $9.59 million in Q1 2024, primarily due to higher unit sales and a price increase [2][15] - Trogarzo sales decreased by 22.4% to $5.17 million, attributed to lower unit sales and increased government rebates [2][17] - Adjusted EBITDA for Q1 2025 was $2.32 million, compared to a loss of $247,000 in the same period last year, indicating improved operational efficiency [26] Recent Developments - The FDA approved the supplemental Biologics License Application for EGRIFTA WR™ on March 25, 2025, which is anticipated to drive further adoption [3][35] - The company faced a temporary supply disruption for EGRIFTA SV due to a manufacturing shutdown, but resumed distribution on February 14, 2025 [6][34] - The approval of the Prior Approval Supplement (PAS) for EGRIFTA SV on April 7, 2025, allows for regular distribution without further FDA authorization [9][35] Research and Development - R&D expenses decreased by 21.2% to $2.97 million in Q1 2025, mainly due to reduced spending on life-cycle management projects [20] - The company presented data highlighting the limitations of using BMI to assess cardiovascular risk in people with HIV, emphasizing the need for better screening methods [10] Guidance and Future Outlook - The company estimates FY2025 revenue to be between $80 million and $83 million, considering the impact of the supply disruption and the new product launch [12] - The transition from EGRIFTA SV to EGRIFTA WR™ is crucial for meeting financial covenants and sustaining revenue growth [36]